9th ESO-ESMO Masterclass in Clinical Oncology

Chair: N. Pavlidis, GR - R. A. Stahel, CH
Scientific Coordinators: W. Gatzemeier, IT - R. Popescu, CH 

AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, colorectal, lung, gynaecological, genito-urinary, head and neck cancers.
Spotlight sessions will facilitate compact update on haematological diseases, palliative and supportive care and communication skills.

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within small groups and discuss these with the chairmen and the faculty.
All participants will reside at the course venue and participation is compulsory throughout the course.
The Masterclass will be entirely in English and fluency in English isnecessary for admission.

THE MASTERCLASS IS:
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on breast, colorectal, gynaecological, head and neck, urological and lung cancers

The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are: Amgen, AstraZeneca, Eli Lilly, GlaxoSmithKline Oncology, Merck and Novartis.

The Masterclass in Clinical Oncology is an ESO-ESMO joint event

The masterclass is held in collaboration with the Flims Alumni Club

ORGANISING SECRETARIAT
Chatrina Melcher
European School of Oncology - Bellinzona Office
Ospedale Regionale Bellinzona e Valli
CH6500 Bellinzona - Switzerland
Tel: +41 91 811 8050
Fax: +4191 811 8051
Email: cmelcher@eso.net

ACCREDITATION
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). The Masterclass has been accredited with 25 ESMO-MORA cat. 1 points.

ACKNOWLEDGEMENTS
ESO wishes to express its appreciation to the Union Bank of Switzerland, UBS, for their consideration and support to the 2010 Masterclass.

FACULTY 

M. Aapro, IMO Clinique de Genolier, Oncology and Haematology Department, Genolier, CH
J. Alexandre, Hospital Hotel-Dieu, Paris, FR
M.R. Alison, Barts and the London School of Medicine and Dentistry, Institute of Cell and Molecular Science, London, UK
M. Bergmann, International Center of Advanced Studies in Health Sciences and Services (ICAS), Ulm, DE
J. Bernier, Genolier Swiss Medical Network, Department of Radiotherapy, Genolier, CH
G. Brown, Royal Marsden Hospital, Department of Radiology, London, UK
J. Capdevila, Vall d'Hebron University Hospital, Medical Oncology Service , Barcelona, ES
F. Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, and International Union Against Cancer (UICC), Geneva, CH
A. Cervantes, Hospital Clinico Universitario, Hematology and Medical Oncology Department, Valencia, ES
G. Curigliano, European Institute of Oncology, Division of Medical Oncology, Milan, IT
J.S. de Bono, The Royal Marsden Hospital, Institue of Cancer Research, Sutton, UK
I. Diel, CGG-Klinik GmbH, Department of Gynaecology, Mannheim, DE
A. Dietz, University of Leipzig, Department of Otolaryngology, Leipzig, DE
T. Eisen, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
L. Fallowfield, CRUK Sussex Psychosocial Oncology Group, Brighton and Sussex Medical School, Falmer, UK
C. Faivre-Finn, Christie Hospital NHS Foundation Trust, Department of Clinical Oncology, Manchester, UK
W. Gatzemeier, Humanitas Clinical Institute, Breast Unit, Rozzano, IT
M. Ghielmini, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
A. Goldhirsch, European Institute of Oncology, Division of Medical Oncology, Milan, IT
A. Horwich, The Royal Marsden Hospital, Sutton, UK
B. Jereczek, European Institute of Oncology, Division of  Radiotherapy, Milan, IT
I. Judson, The Royal Marsden Hospital, Sarcoma Unit, London, UK
J. Maher, Macmillan Cancer Support, Chief Medical Officer, London, UK
K. Miller, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, DE
D. Mosoiu, Hospice Casa Sperantei, Brasov, RO
P. Patel, University of Nottingham, School of Molecular Medical Sciences, Division of Clinical Oncology, Nottingham, UK
N. Pavlidis, University of Ioannina, Division of Medical Oncology, Ioannina, GR
R. Popescu, Hirslanden Klinik Aarau, Tumor Center, Department of Medical Oncology, Aarau, CH
G. Poston, Royal Liverpool University Hospital, Department of Surgery, Liverpool, UK
M. Sailer, International Center for Advanced Studies in Health Sciencies and Services (ICAS), Ulm, DE
C. Scheid, University of Cologne, Clinic I for Internal Medicine, Cologne, DE
D. Sebag-Montefiore, Leeds Cancer Centre, Department of Clinical Oncology, Leeds, UK
E. Senkus-Konefka, Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdansk, PL
R. Stahel, University Hospital Zürich, Clinic and Policlinic for Oncology, Zurich, CH
E. Van Cutsem, University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, BE
H. Van Poppel, U.Z. Gasthuisberg, Department of Urology, Leuven, BE
J. Vermorken, University Hospital Antwerp, Department of Oncology, Edegem, BE
G. Viale, European Institute of Oncology, Department of Pathology, and University of Milano, Milan, IT
G. von Minckwitz, German Breast Group, Neu-Isenburg, DE
W. Weder, University Hospital Zurich, Division of Thoracic Surgery, Zurich, CH

13 March

14 March

15 March

16 March

17 March

18 March